Orbimed Advisors Llc Increased Insmed Inc (NASDAQ:INSM) Stake by $31.48 Million

May 23, 2018 - By Linda Rogers

Insmed Incorporated (NASDAQ:INSM) LogoInvestors sentiment decreased to 1 in 2017 Q4. Its down 2.74, from 3.74 in 2017Q3. It fall, as 27 investors sold INSM shares while 40 reduced holdings. 18 funds opened positions while 49 raised stakes. 73.21 million shares or 49.25% less from 144.25 million shares in 2017Q3 were reported. Bnp Paribas Arbitrage Sa invested 0% in Insmed Incorporated (NASDAQ:INSM). Orbimed Advsr Ltd Liability Company invested in 1.50M shares or 0.59% of the stock. State Of Wisconsin Inv Board holds 0.01% or 74,200 shares. Boothbay Fund Ltd Liability accumulated 14,440 shares. Alliancebernstein Lp holds 0% in Insmed Incorporated (NASDAQ:INSM) or 152,800 shares. Franklin Street Advsrs Nc reported 0.07% in Insmed Incorporated (NASDAQ:INSM). Strs Ohio reported 1,900 shares stake. Sei Invests Company has 0% invested in Insmed Incorporated (NASDAQ:INSM). Royal Bank & Trust Of Canada stated it has 0% in Insmed Incorporated (NASDAQ:INSM). Grp reported 51,539 shares. Teacher Retirement Systems Of Texas invested 0% in Insmed Incorporated (NASDAQ:INSM). Fny Managed Accounts Limited Liability has invested 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Dekabank Deutsche Girozentrale accumulated 35,100 shares. Tudor Inv Et Al holds 9,022 shares or 0.01% of its portfolio. Meeder Asset Mgmt reported 176 shares or 0% of all its holdings.

Samuel Isaly increased its stake in Insmed Inc (NASDAQ:INSM) by 95.61% based on its latest 2018Q1 regulatory filing with the SEC. Orbimed Advisors Llc bought 1.43 million shares as the company’s stock declined 30.16% with the market. The hedge fund run by Samuel Isaly held 2.93 million shares of the health care company at the end of 2018Q1, valued at $65.94M, up from 1.50 million at the end of the previous reported quarter. Orbimed Advisors Llc who had been investing in Insmed Inc for a number of months, seems to be bullish on the $1.99 billion market cap company. The stock decreased 1.51% or $0.4 during the last trading session, reaching $26.01. About 471,828 shares traded. Insmed Incorporated (NASDAQ:INSM) has risen 31.10% since May 23, 2017 and is uptrending. It has outperformed by 19.55% the S&P500.

Orbimed Advisors Llc, which manages about $6.70 billion and $8.07B US Long portfolio, decreased its stake in Audentes Therapeutics Inc () by 607,538 shares to 3.52 million shares, valued at $105.84 million in 2018Q1, according to the filing. It also reduced its holding in Clovis Oncology Inc (Call) (NASDAQ:CLVS) by 1.91 million shares in the quarter, leaving it with 65,000 shares, and cut its stake in Gilead Sciences Inc (NASDAQ:GILD).

A very big health care fund, Sam Isaly’s Orbimed Advisors makes investments in companies at different levels from those in the public markets to venture capital. The fund main targets are businesses providing medical and pharmaceutical devices and not insurers or hospitals, or it could be said instead of services. Orbimed Advisors Llc is a New York-based hedge fund that was founded by Samuel Isaly. It had more than $6.70 billion assets under management in August, 2014. Taken from Orbimed Advisors latest Adv, the fund reported to have 72 full and part-time employees. Among which 58 performing investment advisory and research functions. The hedge fund had between 11-25 clients.

Insmed Incorporated (NASDAQ:INSM) Ratings Coverage

Among 6 analysts covering Insmed (NASDAQ:INSM), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Insmed had 6 analyst reports since January 4, 2018 according to SRatingsIntel. The firm has “Outperform” rating by Credit Suisse given on Monday, April 23. The rating was maintained by Leerink Swann on Wednesday, March 14 with “Buy”. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, January 4. Stifel Nicolaus upgraded Insmed Incorporated (NASDAQ:INSM) on Thursday, January 4 to “Buy” rating. Robert W. Baird maintained it with “Buy” rating and $42.0 target in Thursday, January 4 report.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company has market cap of $1.99 billion. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It currently has negative earnings. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension.

More notable recent Insmed Incorporated (NASDAQ:INSM) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing” on May 23, 2018, also Streetinsider.com with their article: “Insmed (INSM) Announces FDA Acceptance for Filing of NDA for ALIS in NTM Lung Disease Caused by MAC” published on May 16, 2018, Seekingalpha.com published: “Insmed’s (INSM) CEO William Lewis on Q1 2018 Results – Earnings Call Transcript” on May 04, 2018. More interesting news about Insmed Incorporated (NASDAQ:INSM) were released by: Seekingalpha.com and their article: “Insmed’s ALIS successful in late-stage lung disease study” published on May 23, 2018 as well as Nasdaq.com‘s news article titled: “Insmed Announces Presentations at the American Thoracic Society 2018 International Conference” with publication date: May 22, 2018.

Insmed Incorporated (NASDAQ:INSM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: